PCDH7 and lung adenocarcinoma: In the TCGA–LUAD cohort (lung adenocarcinoma), patients with high expression of PCDH7 appear to have a poor prognosis (Figures 2F–H, overall survival, p = 0.003; disease-free survival, p = 0.002; progression-free survival, p = 0.003).